RO 0506997

Drug Profile

RO 0506997

Alternative Names: A4I antagonist; RO0506997

Latest Information Update: 18 Feb 2014

Price : $50

At a glance

  • Originator Roche
  • Class
  • Mechanism of Action Integrin alpha4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 01 Jan 2008 Discontinued - Phase-II for Rheumatoid arthritis in Spain (PO)
  • 01 Jan 2008 Discontinued - Phase-II for Multiple sclerosis in Spain (PO)
  • 24 Mar 2005 Phase-II clinical trials in Rheumatoid arthritis in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top